BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30977516)

  • 1. The expression of Platelet-derived Growth factor receptors (PDGFRs) and their correlation with overall survival of patients with ovarian cancer.
    Szubert S; Moszynski R; Szpurek D; Romaniuk B; Sajdak S; Nowicki M; Michalak S
    Ginekol Pol; 2019; 90(5):242-249. PubMed ID: 30977516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.
    Henriksen R; Funa K; Wilander E; Bäckström T; Ridderheim M; Oberg K
    Cancer Res; 1993 Oct; 53(19):4550-4. PubMed ID: 8402626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium.
    Dabrow MB; Francesco MR; McBrearty FX; Caradonna S
    Gynecol Oncol; 1998 Oct; 71(1):29-37. PubMed ID: 9784315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of BTG3 was linked to carcinogenesis, aggressiveness, and prognosis of ovarian carcinoma.
    Deng B; Zhao Y; Gou W; Chen S; Mao X; Takano Y; Zheng H
    Tumour Biol; 2013 Oct; 34(5):2617-24. PubMed ID: 23657964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
    Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of PDGF ligands and receptors in the tumor prone ovary of follitropin receptor knockout (FORKO) mouse.
    Chen X; Aravindakshan J; Yang Y; Tiwari-Pandey R; Sairam MR
    Carcinogenesis; 2006 May; 27(5):903-15. PubMed ID: 16344272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
    Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
    Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis.
    Qian H; Appiah-Kubi K; Wang Y; Wu M; Tao Y; Wu Y; Chen Y
    Crit Rev Oncol Hematol; 2018 Jul; 127():15-28. PubMed ID: 29891108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
    Donnem T; Al-Saad S; Al-Shibli K; Andersen S; Busund LT; Bremnes RM
    J Thorac Oncol; 2008 Sep; 3(9):963-70. PubMed ID: 18758297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
    Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
    Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.
    Moreno L; Popov S; Jury A; Al Sarraj S; Jones C; Zacharoulis S
    J Neurooncol; 2013 Jan; 111(2):169-76. PubMed ID: 23135775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
    Mathey S; Graeser MK; Zu Eulenburg C; Woelber L; Trillsch F; Jaenicke F; Müller V; Milde-Langosch K; Mahner S
    Oncology; 2013; 85(2):69-77. PubMed ID: 23860180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis.
    Iussich S; Maniscalco L; Di Sciuva A; Iotti B; Morello E; Martano M; Gattino F; Buracco P; De Maria R
    Vet Comp Oncol; 2017 Jun; 15(2):462-469. PubMed ID: 26833575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High tumor cell vimentin expression indicates prolonged survival in patients with ovarian malignant tumors.
    Szubert S; Koper K; Dutsch-Wicherek MM; Jozwicki W
    Ginekol Pol; 2019; 90(1):11-19. PubMed ID: 30756366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer.
    Steele IA; Edmondson RJ; Bulmer JN; Bolger BS; Leung HY; Davies BR
    Oncogene; 2001 Sep; 20(41):5878-87. PubMed ID: 11593393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.